Abstract
Recombinant adeno-associated virus (rAAV) vectors have become increasingly popular in research and clinical trials due to their efficient gene transfer and long-term expression in tissues including brain. In addition, rAAV has demonstrated an impressive safety profile in gene therapy trials. The emergence of rAAV serotypes with different cell tropisms and distribution properties has allowed scientists to tailor serotypes to specific experimental needs. AAV does not have a cytopathic effect; therefore, purification methods require extraction of the viral vector from the cell. This involves gradient ultracentrifugation of the cellular extract sometimes followed by chromatography. This chapter describes a small-scale production method for rAAV purification from ten to twenty 15 cm plates of human embryonic kidney-derived 293B cells (HEK 293) cells that can yield approximately 300 μl of a 5 × 1012 to 1 × 1013 genome copies/ml viral preparation final concentration.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ayuso E, Mingozzi F, Bosch F (2010) Production, purification and characterization of adeno-associated vectors. Curr Gene Ther 10(6):423–436
Virag T, Cecchini S, Kotin RM (2009) Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy. Hum Gene Ther 20(8):807–817
Carter BJ, Antoni BA, Klessig DF (1992) Adenovirus containing a deletion of the early region 2A gene allows growth of adeno-associated virus with decreased efficiency. Virology 191:473–476
Ward P et al (1998) Role of the adenovirus DNA-binding protein in in vitro adeno-associated virus DNA replication. J Virol 72(1):420–427
Janik JE et al (1989) Efficient synthesis of adeno-associated virus structural proteins requires both adenovirus DNA binding protein and VA I RNA. Virology 168:320–329
Chang LS, Shenk T (1990) The adenovirus DNA-binding protein stimulates the rate of transcription directed by adenovirus and adeno-associated virus promoters. J Virol 64:2103–2109
Nash K, Chen W, Muzyczka N (2008) Complete in vitro reconstitution of adeno-associated virus DNA replication requires the minichromosome maintenance complex proteins. J Virol 82(3):1458–1464
Zolotukhin S et al (1999) Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6(6):973–985
Binny CJ, Nathwani AC (2012) Vector systems for prenatal gene therapy: principles of adeno-associated virus vector design and production. Methods Mol Biol 891:109–131
Chahal PS et al (2014) Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery. J Virol Methods 196:163–173
Zolotukhin S et al (2002) Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28(2):158–167
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Burger, C., Nash, K.R. (2016). Small-Scale Recombinant Adeno-Associated Virus Purification. In: Manfredsson, F. (eds) Gene Therapy for Neurological Disorders. Methods in Molecular Biology, vol 1382. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3271-9_7
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3271-9_7
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3270-2
Online ISBN: 978-1-4939-3271-9
eBook Packages: Springer Protocols